Akero Therapeutics Inc (STU:0K4)
€ 29.02 -1.63 (-5.32%) Market Cap: 2.04 Bil Enterprise Value: 1.40 Bil PE Ratio: 0 PB Ratio: 3.02 GF Score: 34/100

Akero Therapeutics Inc at Bank of America Healthcare Conference Transcript

May 11, 2022 / 03:40PM GMT
Release Date Price: €9.35 (-3.11%)
Dan Lundquist
BofA Securities, Inc. - Analyst

Hi, my name is Dan Lundquist. Thank you very much for joining the Wednesday events. I'm the healthcare specialist to BofA and very pleased to welcome with me today Kitty Yale from Akero. She's the Chief Development Officer. She does have some presentation slides, so she'll go through those. And then if we have some time, we have some Q&A as well.

All right. Thank you, Kitty.

Kitty Yale
Akero Therapeutics, Inc. - Chief Development Officer

Thank you. So good morning, everybody. As Dan said, I am Kitty Yale. I am the Chief Development Officer at Akero. And Akero is developing Efruxifermin or for short, we describe it as EFX as a potential best-in-class NASH therapy.

An EFX is a differentiated Fc-FGF21 fusion protein that's been engineered to mimic the balanced biological activity of native FGF21.

The data I am going to share with you today is from our Phase 2a program. And we are pleased that some of the data that we generated in our Phase 2 program is some of the strongest of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot